Genotype - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Genotype

The Experts below are selected from a list of 1415151 Experts worldwide ranked by ideXlab platform

Genotype – Free Register to Access Experts & Abstracts

Ping Xu – One of the best experts on this subject based on the ideXlab platform.

  • the genetic variations in dna repair genes ercc2 and xrcc1 were associated with the overall survival of advanced non small cell lung cancer patients
    Cancer Medicine, 2016
    Co-Authors: S Wang, Jianzhong Wang, Qing Wang, Kai Zhang, Xiaohua Hong, Qifei Deng, Xiaomin Zhang, Meian He, Tangchun Wu, Ping Xu
    Abstract:

    It was reported that DNA repair can confer cancer cell resistance to therapeutic treatments by activating antiapoptotic cellular defense. We hypothesized that genetic variants of DNA repair genes may be associated with lung cancer prognosis. Seventeen tagging single-nuclnucleotideypolymorphism (tagSNPs) selected from 12 DNA repair genes were Genotyped in 280 advanced non-small-cell lung cancer (NSCLC) patients by TaqMan assay. The associations of these SNPs and overall survival of advanced NSCLC patients were investigated. Advanced NSCLC patients carrying ERCC2 rs50872 CT+TT Genotypes had significantly longer median survival time (MST) and decreased death risk than patients with rs50872 CC Genotype [log-rank P = 0.031; adjusted HR(95% CI) = 0.73 (0.55-0.98), P = 0.033]. These effects were mainly seen among younger patients (≤65 years old) [HR(95% CI) = 0.57 (0.37-0.87), P = 0.010], patients without surgery [HR(95% CI) = 0.68 (0.47-0.98), P = 0.036] but with chemotherapy [HR(95% CI) = 0.64 (0.46-0.91), P = 0.012] or radiotherapy [HR(95% CI) = 0.58 (0.38-0.89), P = 0.013]. Meanwhile, compared to advanced NSCLC patients with rs25487 GG Genotype, patients carrying XRCC1 rs25487 GA+AA Genotypes had significantly shorter MST (MST = 11.7 vs. 16.7, log-rank P = 0.048). In addition, advanced NSCLC patients carrying the ERCC2 rs50872 CC in combination with XRCC1 rs25487 GA+AA Genotype had the shortest MST (11.2 month) and highest death risk [HR(95% CI) = 1.70 (1.15-2.52), P = 0.008] when compared with those carrying rs50872 CT+TT and rs25487 GG Genotype (MST = 22.0 month). The ERCC2 rs50872 T allele was associated with favorable but XRCC1 rs25487 A allele with bad survival for advanced NSCLC in Chinese population, which may offer novel biomarkers for predicting clinical outcomes.

Sung Jin Yoon – One of the best experts on this subject based on the ideXlab platform.

  • Association of SUMO1 and UBC9 Genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy
    The Pharmacogenomics Journal, 2010
    Co-Authors: Sung Jin Yoon
    Abstract:

    Irinotecan induces small ubiquitin-like modifier (SUMO)-1 conjugation to topoisomerase-I, leading to enhanced sensitivity to irinotecan. In this study, we Genotyped SUMO1 and UBC9 polymorphisms in 147 non-small-cell lung cancer (NSCLC) treated with irinotecan chemotherapy to investigate the association between Genotypes and tumor response rate. Immunohistochemistry for SUMO1 and UBC9 was performed in 42 tumor samples and correlated with Genotypes. The UBC9 10920CG Genotype was associated with significantly higher response rate than the C/C Genotype (81 vs 37%, P =0.0002). This predictive effect on tumor response was also seen in multivariate analysis (odds ratio=8.5, P =0.003). Moreover, tumors arising from the UBC9 10920CG Genotype were associated with higher prevalence of SUMO1 overexpression compared with those with CC Genotype (78 vs 31%, P =0.021). This finding suggests that the UBC9 10920CG Genotype enhances sensitivity to irinotecan chemotherapy in advanced NSCLC through upregulation of SUMO1 in tumor cells.

Sunwen Chou – One of the best experts on this subject based on the ideXlab platform.

  • association of cytomegalovirus Genotype with graft rejection after liver transplantation
    Transplantation, 1998
    Co-Authors: Hugo R Rosen, Christopher L Corless, John M Rabkin, Sunwen Chou
    Abstract:

    Background. The envelope glycoprotein gB of human cytocytomegalovirus (CMV) occurs as one of four main Genotypes. Some previous studies have proposed a relationship of CMV gB Genotype to the frequency of symptomatic infection and to clinical outcomes in both transplant and human immunodeficiency virus-infected populations. Our aim was to define the distribution of CMV gB Genotypes and the impact on acute cellular rejection and graft/patient survival after orthotopic liver transplantation (OLT). Methods. Between October 1988 and December 1996, 325 patients underwent cyclosporine-based OLT at our center. CMV infection was surveyed prospectively and defined as viral isolation from blood or urine; 53 (16%) patients had detectable CMV. Isolates were Genotyped by polymerase chain reaction amplification and restriction digest analysis. Results. The distribution of CMV Genotypes was: gB1, 19 (36%) patients; gB2, 15 (28%) patients; gB3, 13 (24%) patients; and gB4, 4 (8%) patients. Two patients (4%) had mixed infection (1 + 3, 1 + 4). Age, preOLT diagnosis, use of ganciclovir prophylaxis, basal immunosuppression, mean number of HLA donor/recipient mismatches, and United Network of Organ Sharing status were comparable among patients with different Genotypes. Patients with gB1 had a significantly higher mean number of acute rejection episodes (1.52±0.30 vs. 0.67±0.22; P=0.027). However, there was no difference in rejection severity, including OKT3 usage or FK506 conversion, or development of chronic rejection among patients with different Genotypes. The gB Genotype did not affect the development of symptomatic or tissue-invasive CMV disease, detected in 15 patients. Actuarial rates of patient (odds ratio [OR] 3.0; confidence interval [CI] 1.49-6.0) and graft (OR 2.57; CI 1.25-5.22) survival were significantly diminished in the group with CMV infection versus those without CMV (P<0.0001 for both), but there was no association with CMV Genotype. Conclusions. (1) Patients with CMV infection had significantly reduced patient and graft survival rates at 1 and 5 years after OLT as compared with OLT recipients without CMV infection. (2) CMV Genotype gB1 was associated with a higher mean number of acute rejection episodes.

S Wang – One of the best experts on this subject based on the ideXlab platform.

  • the genetic variations in dna repair genes ercc2 and xrcc1 were associated with the overall survival of advanced non small cell lung cancer patients
    Cancer Medicine, 2016
    Co-Authors: S Wang, Jianzhong Wang, Qing Wang, Kai Zhang, Xiaohua Hong, Qifei Deng, Xiaomin Zhang, Meian He, Tangchun Wu, Ping Xu
    Abstract:

    It was reported that DNA repair can confer cancer cell resistance to therapeutic treatments by activating antiapoptotic cellular defense. We hypothesized that genetic variants of DNA repair genes may be associated with lung cancer prognosis. Seventeen tagging single-nucleotide polymorphism (tagSNPs) selected from 12 DNA repair genes were Genotyped in 280 advanced non-small-cell lung cancer (NSCLC) patients by TaqMan assay. The associations of these SNPs and overall survival of advanced NSCLC patients were investigated. Advanced NSCLC patients carrying ERCC2 rs50872 CT+TT Genotypes had significantly longer median survival time (MST) and decreased death risk than patients with rs50872 CC Genotype [log-rank P = 0.031; adjusted HR(95% CI) = 0.73 (0.55-0.98), P = 0.033]. These effects were mainly seen among younger patients (≤65 years old) [HR(95% CI) = 0.57 (0.37-0.87), P = 0.010], patients without surgery [HR(95% CI) = 0.68 (0.47-0.98), P = 0.036] but with chemotherapy [HR(95% CI) = 0.64 (0.46-0.91), P = 0.012] or radiotherapy [HR(95% CI) = 0.58 (0.38-0.89), P = 0.013]. Meanwhile, compared to advanced NSCLC patients with rs25487 GG Genotype, patients carrying XRCC1 rs25487 GA+AA Genotypes had significantly shorter MST (MST = 11.7 vs. 16.7, log-rank P = 0.048). In addition, advanced NSCLC patients carrying the ERCC2 rs50872 CC in combination with XRCC1 rs25487 GA+AA Genotype had the shortest MST (11.2 month) and highest death risk [HR(95% CI) = 1.70 (1.15-2.52), P = 0.008] when compared with those carrying rs50872 CT+TT and rs25487 GG Genotype (MST = 22.0 month). The ERCC2 rs50872 T allele was associated with favorable but XRCC1 rs25487 A allele with bad survival for advanced NSCLC in Chinese population, which may offer novel biomarkers for predicting clinical outcomes.

Marcel D Waldinger – One of the best experts on this subject based on the ideXlab platform.

  • serotonin transporter promoter region 5 httlpr polymorphism is not associated with paroxetine induced ejaculation delay in dutch men with lifelong premature ejaculation
    Korean Journal of Urology, 2014
    Co-Authors: Paddy K C Janssen, Aeilko H Zwinderman, Berend Olivier, Marcel D Waldinger
    Abstract:

    Purpose: To investigate the association between the 5-HT-transporter-gene-linked promoter region (5-HTTLPR) polymorphism and 20-mg paroxetine-induced ejaculation delay in men with lifelong premature ejaculation (LPE). Materials and Methods: This was a prospective study of 10 weeks of paroxetine treatment in 54 men with LPE. Intravaginal ejaculation latency time (IELT) was measured by stopwatch. Controls consisted of 92 Caucasian men. All men with LPE were Genotyped for the 5-HTTLPR polymorphism. Allele frequencies and Genotypes of short (S) and long (L) variants of the polymorphism were compared between patients and controls. Associations between the LL, SL, and SS Genotypes and fold increase of mean IELT were investigated. Results: Of the 54 patients, 43 (79.6%) responded to 20-mg paroxetine treatment with an ejaculation delay, whereas 11 patients (20.4%) did not respond; 44%, 18%, and 18% of the patients showed a fold increase in mean IELT of 2-10, 10-20, and more than 20, respectively. Of the 54 men, 14 (25.9%) had the LL Genotype, 29 (53.7%) had the SL Genotype, and 11 (20.4%) had the SS Genotype. In the 92 controls, the LL, SL, and SS Genotypes were present in 27 (29.3%), 41 (44.6%), and 24 (26.1%), respectively. No statistically significant differences were found in 5-HTTLPR allelic variations or in 5-HTTLPR gene variations. In all men treated with 20 mg paroxetine, analysis of variance of the natural logarithm of fold increase in the IELT showed no statistically significant difference according to Genotype (p=0.83). Conclusions: The 5-HTTLPR polymorphism is not associated with daily 20-mg paroxetine treatment-induced ejaculation delay in men with LPE.